|
|
|
|
LEADER |
01930nam a2200325 u 4500 |
001 |
EB001839674 |
003 |
EBX01000000000000001003663 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
180702 r ||| eng |
245 |
0 |
0 |
|a Angiotensin-converting enzyme (ACE) inhibitors
|h Elektronische Ressource
|b a review of the comparative clinical and cost-effectiveness
|
246 |
3 |
1 |
|a ACE inhibitors
|
260 |
|
|
|a [Ottawa]
|b Canadian Agency for Drugs and Technologies in Health
|c 12 June 2015, 2015
|
300 |
|
|
|a 1 PDF file (21 pages)
|b illustrations
|
505 |
0 |
|
|a Includes bibliographical references
|
653 |
|
|
|a Hypertension / drug therapy
|
653 |
|
|
|a Comparative Effectiveness Research
|
653 |
|
|
|a Angiotensin-Converting Enzyme Inhibitors / therapeutic use
|
653 |
|
|
|a Cost-Benefit Analysis
|
653 |
|
|
|a Myocardial Infarction / drug therapy
|
653 |
|
|
|a Diabetic Nephropathies / drug therapy
|
653 |
|
|
|a Diuretics / therapeutic use
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a Rapid response report: summary with critical appraisal
|
500 |
|
|
|a Title from PDF caption title
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK304523
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a This purpose of this report is to update a 2008 CADTH Rapid Response report on the comparative clinical and cost-effectiveness of angiotensin converting enzyme (ACE) inhibitors. In addition, it aims to examine the effectiveness of the combination of ACE inhibitors and diuretics compared to ACE inhibitors alone. The finding of this report can help produce clinical evidence as well as policy directions on the best and optimum use of individual ACE inhibitors for hypertension (HTN), heart failure (HF), myocardial infarction (MI), and diabetic nephropathy
|